Therapeutic potential of resveratrol: the in vivo evidence.
Resveratrol, a constituent of red wine, has long been suspected to have cardioprotective effects. Interest in this compound has been renewed in recent years, first from its identification as a chemopreventive agent for skin cancer, and subsequently from reports that it activates sirtuin deacetylases and extends the lifespans of lower organisms. Despite scepticism concerning its bioavailability, a growing body of in vivo evidence indicates that resveratrol has protective effects in rodent models of stress and disease. Here, we provide a comprehensive and critical review of the in vivo data on resveratrol, and consider its potential as a therapeutic for humans.
Baur
Joseph A
JA
Paul F. Glenn Laboratories for the Biological Mechanisms of Aging, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, Massachusetts 02115, USA.
Sinclair
David A
DA
D000375:Aging / Q000187:drug effects / Q000502:physiology; D000818:Animals; D006331:Heart Diseases / Q000188:drug therapy / Q000517:prevention & control; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000517:prevention & control; D009203:Myocardial Infarction / Q000188:drug therapy / Q000517:prevention & control; D009369:Neoplasms / Q000188:drug therapy / Q000517:prevention & control; D020011:Protective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000077185:Resveratrol; D013267:Stilbenes / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D020521:Stroke / Q000188:drug therapy / Q000517:prevention & control
D020011:Protective Agents; D013267:Stilbenes; D000077185:Resveratrol